Pharmafile Logo
Pharmafocus logo
Advanced Search

Deals

Showing 15 posts of 19 posts found.

ipos0_l

Sanofi will pay Regeneron $582m in deal restructuring

January 7, 2019
Sales and Marketing Deals, Regeneron, Sanofi, biotech, pharma

French pharmaceutical giant Sanofi will pay US biotech Regeneron $582 million, as part of a restructuring of an earlier deal …

News
astrazeneca_building_white

AstraZeneca licenses skin-condition drug to Leo Pharma for $115 million upfront

July 1, 2016
Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Deals, Licencing, Loe Pharna, Valeant, drug development

UK drug firm AstraZeneca (LSE: AZN) said it has licenced its drug for skin diseases to Leo Pharma for an …

News
teva_copy

Mayne Pharma to buy a portfolio of Teva’s generic drugs for $652 million

June 29, 2016
Research and Development, Sales and Marketing Allergan, Deals, Mayne Pharma, Teva, generics, merger and acquisition

Australia’s Mayne Pharma Group Ltd (ASX: MYX) said it will acquire US generic products from Israel-based drugmaker Teva Pharmaceuticals (NYSE: …

News

Bayer offers $62 billion for Monsanto in all cash deal

May 23, 2016
Research and Development, Sales and Marketing Bayer, Deals, Financial, Merger & Acquisition, monsanto

German pharma and crop sciences giant Bayer (ETR: BAYN) has made an unsolicited $62 billion all-cash offer for Monsanto Co …

News
celltherapy

Cell Therapy signs £12.5 million licensing deal with Daiichi Sankyo for heart failure treatment

May 10, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Daiichi Sankyo, Deals, cell therapy, heart failure, licensing

UK-based Cell Therapy on Tuesday said it has signed a £12.5 million licensing deal with Japan’s Daiichi Sankyo (TYO: 4568) …

News
medivation

Medivation maybe mulling sale as bidding race heats up – Reports

May 10, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Deals, M&A, MA, Medivation, Pfizer, Sanofi

Cancer drugmaker Medivation (Nasdaq: MDVN) is evaluating a potential sale following the recent string of offers from big pharma firms, …

News
amgen_flag

Amgen looking to join the fray, mulling Medivation bid – Reports

May 5, 2016
Research and Development, Sales and Marketing Amgen, AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi

Biotech firm Amgen (Nasdaq: AMGN) is mulling a bid for Medivation (Nasdaq: MDVN), the latest to join the growing list …

News

Pfizer joins the race, bids for Medivation – Reports

May 4, 2016
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi

US pharma giant Pfizer (NYSE: PFE) is rumoured to have joined the list of suitors vying for the Medivation (Nasdaq: …

News
shirelogo

Shire reassures Baxalta acquisition on track in the aftermath of Pfizer-Allergan breakup

April 7, 2016
Business Services, Sales and Marketing AbbVie, Allergan, Baxalta, Deals, Financial, Merger & Acquisition, Pfizer, Shire

Ireland-headquartered Shire Plc (LSE: SHP) has reassured its $32-billion merger deal with US-based Baxlata (NYSE: BXLT) remains on track in …

News

Blueprint Medicines agrees $1 billion-plus deal with Roche for cancer therapy

March 16, 2016
Business Services, Research and Development, Sales and Marketing Blueprint Medicines, Deals, Immunokinases, Roche, drug development

Blueprint Medicines Corp (Nasdaq: BPMC) said it has signed an over $1 billion deal with oncology drug giant Roche (SIX: ROG) …

News
personal-95715_640

Mirror. Signal. Merger. How to deal with a pharma takeover

December 14, 2015
Manufacturing and Production, Medical Communications, Sales and Marketing Deals, acquisition, buyouts, mergers, takeovers

So 2015 has been a record year for M&A in the pharma industry.The Financial Times has called this “the most …

Feature
Allergan

2015’s top five mergers and acquisitions in a record-breaking year

October 19, 2015
Sales and Marketing Deals, acquisitions, mergers, pharma, takeovers

A new report from analysts MergerMarket reveals that mergers and acquisitions so far in 2015 have surpassed the same 2014 …

Feature

Hundreds of jobs threatened after big pharma deals close

April 7, 2015
Medical Communications, Research and Development, Sales and Marketing Deals, GSK, Jobs, Novartis, US, Valeant, job losses, redundancy, salix

Fresh from deals worth a combined $34 billion, GSK and Salix Pharmaceuticals have announced company restructures that have placed more …

News
Valeant image

Valeant to buy Salix in $14.5 billion move

February 23, 2015
Sales and Marketing Deals, Heptares, Valeant, mergers, salix, sosei

Valeant has agreed a deal to acquire US-based speciality manufacturer of gastrointestinal drugs Salix in a move worth around $14.5 …

News
Astrazeneca image

AstraZeneca signs MIT/Harvard research deal

September 17, 2012
Business Services, Research and Development, Sales and Marketing AstraZeneca, Deals, Havard, MIT

AstraZeneca has signed a two-year collaboration with an academic institution – affiliated to the illustrious universities MIT and Harvard – …

News

Latest content

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024

PeptiDream and Novartis extend peptide discovery collaboration

April 30, 2024

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

April 29, 2024